Ranjit Bindra
Professor Yale Univerisity
Seminars
Wednesday 18th February 2026
Targeted DNA Modification as a Novel Glioma Therapy: Journey from Bench to Biotech to Pharma…to Bedside…
4:00 pm
- Tracing the journey of a groundbreaking technology, targeted DNA modification, from its initial discovery at the research bench to its successful translation into a biotech platform
- Detailing the strategic and financial evolution of the technology, highlighting how it attracted investment and ultimately led to a significant acquisition by a major pharmaceutical company
- Examining the path forward for this therapy, exploring how a promising scientific concept, now backed by a major pharma’s resources, is being advanced from the lab to clinical development and ultimately, to the patient’s bedside
Wednesday 18th February 2026
Pharma Perspectives Panel Discussion: Successfully Engaging with Large Pharma Companies to Secure Future Partnerships for GBM Therapeutic Development
3:30 pm
- Identifying specific data packages, preclinical models and clinical milestones that will make a GBM asset attractive for a partnership, beyond scientific novelty
- Strategies for pitching, due diligence considerations and building collaborative relationships to effectively engage with big pharma business development teams to secure a deal
- Insights into creative deal terms, IP considerations and defining clear roles and responsibilities to ensure both partners are aligned on the path to clinical and commercial success
